Skip to main content

Articles

Page 1 of 30

  1. Amyotrophic Lateral Sclerosis (ALS), a neurodegenerative disease involving loss of motor neurons, typically results in death within 3–5 years of disease onset. Although roughly 10% of cases can be linked to a ...

    Authors: Adam N. Trautwig, Edward J. Fox, Eric B. Dammer, Anantharaman Shantaraman, Lingyan Ping, Duc M. Duong, Caroline M. Watson, Fang Wu, Seneshaw Asress, Qi Guo, Allan I. Levey, James J. Lah, Federico Verde, Alberto Doretti, Antonia Ratti, Nicola Ticozzi…
    Citation: Molecular Neurodegeneration 2025 20:58
  2. The development of anti-amyloid-beta (Aβ) immunotherapies as the first disease modifying therapy for Alzheimer’s Disease (AD) is a breakthrough of basic research and translational science.

    Authors: Philip Pikus, R. Scott Turner and G. William Rebeck
    Citation: Molecular Neurodegeneration 2025 20:57
  3. Tau protein plays a critical role in the physiological functioning of the central nervous system by providing structural integrity to the cytoskeletal architecture of neurons and glia through microtubule assem...

    Authors: Neil Donison, Jacqueline Palik, Kathryn Volkening and Michael J. Strong
    Citation: Molecular Neurodegeneration 2025 20:56
  4. While the temporal profile of amyloid (Aβ) and tau cerebrospinal fluid (CSF) biomarkers along the Alzheimer’s disease (AD) continuum is well-studied, chronological changes of CSF proteins reflecting other dise...

    Authors: Sophia Weiner, Mathias Sauer, Laia Montoliu-Gaya, Andrea L. Benedet, Nicholas J. Ashton, Fernando Gonzalez-Ortiz, Joel Simrén, Nesrine Rahmouni, Cecile Tissot, Joseph Therriault, Stijn Servaes, Jenna Stevenson, Ville Leinonen, Tuomas Rauramaa, Mikko Hiltunen, Pedro Rosa-Neto…
    Citation: Molecular Neurodegeneration 2025 20:52
  5. Genome-wide association studies (GWAS) of Alzheimer’s disease (AD) have identified a plethora of risk loci. However, the disease variants/genes and the underlying mechanisms have not been extensively studied.

    Authors: Xiaojie Zhao, Yan Li, Siwei Zhang, Ari Sudwarts, Hanwen Zhang, Alena Kozlova, Matthew J. Moulton, Lindsey D. Goodman, Zhiping P. Pang, Alan R. Sanders, Hugo J. Bellen, Gopal Thinakaran and Jubao Duan
    Citation: Molecular Neurodegeneration 2025 20:51
  6. Biallelic loss-of-function variants in TYROBP and TREM2 cause autosomal recessive presenile dementia with bone cysts known as Nasu-Hakola disease (NHD, alternatively polycystic lipomembranous osteodysplasia with ...

    Authors: Henna Martiskainen, Roosa-Maria Willman, Päivi Harju, Sami Heikkinen, Mette Heiskanen, Stephan A. Müller, Rosa Sinisalo, Mari Takalo, Petra Mäkinen, Teemu Kuulasmaa, Viivi Pekkala, Ana Galván del Rey, Sini-Pauliina Juopperi, Heli Jeskanen, Inka Kervinen, Kirsi Saastamoinen…
    Citation: Molecular Neurodegeneration 2025 20:50
  7. In recent years, the seed amplification assay (SAA) has enabled the identification of pathological TDP-43 in the cerebrospinal fluid (CSF) and olfactory mucosa (OM) of patients with genetic forms of frontotemp...

    Authors: Maria Vizziello, Ilaria Linda Dellarole, Arianna Ciullini, Riccardo Pascuzzo, Annalisa Lombardo, Floriana Bellandi, Luigi Celauro, Claudia Battipaglia, Emilio Ciusani, Ambra Rizzo, Marcella Catania, Grazia Devigili, Sara Adriana Della Seta, Valentina Margiotta, Monica Consonni, Veronica Faltracco…
    Citation: Molecular Neurodegeneration 2025 20:49
  8. Autosomal Dominant Alzheimer's Disease (ADAD), caused by mutations in Presenilins (PSEN1/2) and Amyloid Precursor Protein (APP) genes, typically manifests with early onset (< 65 years). Age at symptom onset (AAO)...

    Authors: Sara Gutiérrez Fernández, Cristina Gan Oria, Dieter Petit, Wim Annaert, John M. Ringman, Nick C. Fox, Natalie S. Ryan and Lucía Chávez-Gutiérrez
    Citation: Molecular Neurodegeneration 2025 20:48
  9. Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that primarily affects the motor neurons, causing progressive muscle weakness and paralysis. While research has focused on understanding patho...

    Authors: Natalie Grima, Andrew N. Smith, Claire E. Shepherd, Lyndal Henden, Thiri Zaw, Luke Carroll, Dominic B. Rowe, Matthew C. Kiernan, Ian P. Blair and Kelly L. Williams
    Citation: Molecular Neurodegeneration 2025 20:40
  10. Apolipoprotein E (APOE- gene; apoE- protein) is the strongest genetic modulator of late-onset Alzheimer’s disease (AD), with its three major isoforms conferring risk for disease ε2 < ε3 < ε4. Emerging protective ...

    Authors: Abdel Ali Belaidi, Ashley I. Bush and Scott Ayton
    Citation: Molecular Neurodegeneration 2025 20:47
  11. Lewy body dementia (LBD) encompasses neurodegenerative dementias characterized by cognitive fluctuations, visual hallucinations, and parkinsonism. Clinical differentiation of LBD from Alzheimer’s disease (AD) ...

    Authors: Suelen Lucio Boschen, Aarushi A. Mukerjee, Ayman H. Faroqi, Ben E. Rabichow and John Fryer
    Citation: Molecular Neurodegeneration 2025 20:46
  12. Genetic variation in Transmembrane protein 106B (TMEM106B) is known to influence the risk and presentation in several neurodegenerative diseases and modifies healthy aging. While evidence from human studies su...

    Authors: Jolien Perneel, Miranda Lastra Osua, Sara Alidadiani, Nele Peeters, Linus De Witte, Bavo Heeman, Simona Manzella, Riet De Rycke, Mieu Brooks, Ralph B. Perkerson, Elke Calus, Wouter De Coster, Manuela Neumann, Ian R. A. Mackenzie, Debby Van Dam, Bob Asselbergh…
    Citation: Molecular Neurodegeneration 2025 20:45
  13. The epoxyeicosatrienoic acids (EETs) are derivatives of the arachidonic acid metabolism with anti-inflammatory activities. However, their efficacy is limited due to the rapid hydrolysis by soluble epoxide hydr...

    Authors: Shuo Wang, Chuangye Qi, Chetan Rajpurohit, Baijayanti Ghosh, Wen Xiong, Baiping Wang, Yanyan Qi, Sung Hee Hwang, Bruce D. Hammock, Hongjie Li, Li Gan and Hui Zheng
    Citation: Molecular Neurodegeneration 2025 20:44
  14. There is currently no effective therapy for prion diseases. The glymphatic system is an organized system of perivascular spaces that facilitates the removal of metabolic waste from the brain. This study demons...

    Authors: Mohammed Zayed, Yong-Chan Kim and Byung-Hoon Jeong
    Citation: Molecular Neurodegeneration 2025 20:42
  15. GPNMB has been discussed as a potential therapeutic target in GRN-mediated neurodegeneration, based on the observed reproducible upregulation in FTD-GRN cerebrospinal fluid (CSF) and post-mortem brain. However, t...

    Authors: Rebecca L. Wallings, Drew A. Gillett, Hannah A. Staley, Savanna Mahn, Julian Mark, Noelle Neighbarger, Holly Kordasiewicz, Warren D. Hirst and Malú Gámez Tansey
    Citation: Molecular Neurodegeneration 2025 20:41
  16. Immune mechanisms play a fundamental role in Alzheimer’s disease (AD) pathogenesis, suggesting that approaches which target immune cells and immunologically relevant molecules can offer therapeutic opportuniti...

    Authors: Michael R. Duggan, David G. Morgan, Brittani R. Price, Binita Rajbanshi, Alfonso Martin-Peña, Malú Gámez Tansey and Keenan A. Walker
    Citation: Molecular Neurodegeneration 2025 20:39
  17. Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD) are overwhelmingly linked to TDP-43 dysfunction. Mutations in TDP-43 are rare, indicating that the progressive accumulation of exogenous fa...

    Authors: Terry R. Suk, Caroline E. Part, Jenny L. Zhang, Trina T. Nguyen, Meghan M. Heer, Alejandro Caballero-Gómez, Veronica S. Grybas, Paul M. McKeever, Benjamin Nguyen, Tahir Ali, Steve M. Callaghan, John M. Woulfe, Janice Robertson and Maxime W. C. Rousseaux
    Citation: Molecular Neurodegeneration 2025 20:38
  18. Parkinson’s disease (PD) is a multi-system disorder characterized histopathologically by degeneration of dopaminergic neurons in the substantia nigra pars compacta. While the etiology of PD remains multifactorial...

    Authors: Julian R. Mark and Malú Gámez Tansey
    Citation: Molecular Neurodegeneration 2025 20:36
  19. Alzheimer’s disease (AD) is the most common form of dementia globally and is characterised by reduced mitochondrial respiration and cortical deposition of amyloid-β plaques and neurofibrillary tangles comprise...

    Authors: Mary Slayo, Christoph Rummel, Pasindu Hansana Singhaarachchi, Martin Feldotto and Sarah J. Spencer
    Citation: Molecular Neurodegeneration 2025 20:35
  20. DNA damage and DNA damage repair (DDR) dysfunction are insults with broad implications for cellular physiology and have been implicated in various neurodegenerative diseases. Alpha-synuclein (aSyn), a pre-syna...

    Authors: David J. Koss, Olivia Todd, Hariharan Menon, Zoe Anderson, Tamsin Yang, Lucas Findlay, Ben Graham, Pawel Palmowski, Andrew Porter, Nicola Morrice, Lauren Walker, Johannes Attems, Simona S. Ghanem, Omar El-Agnaf, Fiona EN. LeBeau, Daniel Erskine…
    Citation: Molecular Neurodegeneration 2025 20:34
  21. Aggregated alpha-Synuclein (αSyn) is a hallmark pathology in Parkinson’s disease but also one of the most common co-pathologies in Alzheimer’s disease (AD). Preclinical studies suggest that αSyn can exacerbate...

    Authors: Nicolai Franzmeier, Sebastian Niclas Roemer-Cassiano, Alexander Maximilian Bernhardt, Amir Dehsarvi, Anna Dewenter, Anna Steward, Davina Biel, Lukas Frontzkowski, Zeyu Zhu, Johannes Gnörich, Julia Pescoller, Fabian Wagner, Fabian Hirsch, Hannah de Bruin, Rik Ossenkoppele, Carla Palleis…
    Citation: Molecular Neurodegeneration 2025 20:31
  22. Alzheimer’s disease (AD) is neuropathologically characterized by the extracellular deposition of the amyloid-β peptide (Aβ) and the intraneuronal accumulation of abnormal phosphorylated tau (τ)-protein (p-τ). ...

    Authors: Dietmar Rudolf Thal, Koen Poesen, Rik Vandenberghe and Steffi De Meyer
    Citation: Molecular Neurodegeneration 2025 20:33
  23. Tauopathies represent a diverse group of neurodegenerative disorders characterized by the abnormal aggregation of the microtubule-associated protein tau. Despite extensive research, the mechanisms underlying t...

    Authors: Dmytro Morderer, Melissa C. Wren, Feilin Liu, Naomi Kouri, Anastasiia Maistrenko, Bilal Khalil, Nora Pobitzer, Michelle R. Salemi, Brett S. Phinney, Guojun Bu, Na Zhao, Dennis W. Dickson, Melissa E. Murray and Wilfried Rossoll
    Citation: Molecular Neurodegeneration 2025 20:32
  24. Therapeutic development for frontotemporal dementia (FTD) is hindered by the lack of biomarkers that inform susceptibility/risk, prognosis, and the underlying causative pathology. Blood glial fibrillary acidic...

    Authors: Udit Sheth, Linn Öijerstedt, Michael G. Heckman, Launia J. White, Hilary W. Heuer, Argentina Lario Lago, Leah K. Forsberg, Kelley M. Faber, Tatiana M. Foroud, Rosa Rademakers, Eliana Marisa Ramos, Brian S. Appleby, Andrea C. Bozoki, R. Ryan Darby, Bradford C. Dickerson, Kimiko Domoto-Reilly…
    Citation: Molecular Neurodegeneration 2025 20:30
  25. Recent studies highlight the critical role of microglia in neurodegenerative disorders, and emphasize the need for humanized models to accurately study microglial responses. Human-mouse microglia xenotransplan...

    Authors: Lutgarde Serneels, Annerieke Sierksma, Emanuela Pasciuto, Ivana Geric, Arya Nair, Anna Martinez-Muriana, An Snellinx and Bart De Strooper
    Citation: Molecular Neurodegeneration 2025 20:29
  26. Parkinson’s disease (PD) is a leading neurodegenerative disorder characterized by the progressive loss of dopaminergic neurons, contributing to considerable disability worldwide. Current treatments offer only ...

    Authors: Rong-Xin Zhu, Rui-Xue Han, Yue-Han Chen, Lei Huang, Ting Liu, Jingwei Jiang, Cong Wang, Lei Cao, Yang Liu and Ming Lu
    Citation: Molecular Neurodegeneration 2025 20:27
  27. Cytoplasmic alpha-synuclein (αSyn) aggregates are a typical feature of Parkinson’s disease (PD). Extracellular insoluble αSyn can induce pathology in healthy neurons suggesting that PD neurodegeneration may sp...

    Authors: Mª Salomé Sirerol-Piquer, Ana Perez-Villalba, Pere Duart-Abadia, Germán Belenguer, Ulises Gómez-Pinedo, Laura Blasco-Chamarro, Pau Carrillo-Barberà, Azucena Pérez-Cañamás, Victoria Navarro-Garrido, Benjamin Dehay, Miquel Vila, Javier Vitorica, Francisco Pérez-Sánchez and Isabel Fariñas
    Citation: Molecular Neurodegeneration 2025 20:26
  28. The relationship between Alzheimer's disease (AD) and neuroimmunity has gradually begun to be unveiled. Emerging evidence indicates that cyclic GMP-AMP synthase (cGAS) acts as a cytosolic DNA sensor, recognizi...

    Authors: Shuiyue Quan, Xiaofeng Fu, Huimin Cai, Ziye Ren, Yinghao Xu and Longfei Jia
    Citation: Molecular Neurodegeneration 2025 20:25
  29. The parkin-interacting substrate (PARIS, also known as ZNF746) is a transcriptional repressor, whose accumulation and phosphorylation play central pathological roles in Parkinson’s disease (PD). PARIS-induced ...

    Authors: Ji Hun Kim, Sumin Yang, Hyojung Kim, Dang-Khoa Vo, Han-Joo Maeng, Areum Jo, Joo-Heon Shin, Joo-Ho Shin, Hyeon-Man Baek, Gum Hwa Lee, Sung-Hyun Kim, Key-Hwan Lim, Valina L. Dawson, Ted M. Dawson, Jae-Yeol Joo and Yunjong Lee
    Citation: Molecular Neurodegeneration 2025 20:24
  30. Molecular biomarkers of chronic traumatic encephalopathy (CTE) are lacking. We evaluated 18F-MK-6240 tau PET as a biomarker for CTE. Two studies were done: (1) 3H-MK-6240 autoradiography and an in-vitro brain hom...

    Authors: Michael L. Alosco, Jhony Mejía Pérez, Julia E. Culhane, Ranjani Shankar, Christopher J. Nowinski, Samantha Bureau, Nidhi Mundada, Karen Smith, Alinda Amuiri, Breton Asken, Jenna R. Groh, Annalise Miner, Erika Pettway, Sydney Mosaheb, Yorghos Tripodis, Charles Windon…
    Citation: Molecular Neurodegeneration 2025 20:23
  31. Alzheimer’s disease (AD) poses a growing global health challenge as populations age. Recent research highlights the crucial role of peripheral immunity in AD pathogenesis. This review explores how blood-brain ...

    Authors: Shuo Zhang, Yue Gao, Yini Zhao, Timothy Y. Huang, Qiuyang Zheng and Xin Wang
    Citation: Molecular Neurodegeneration 2025 20:22
  32. Normal aging alters brain functions and phenotypes. However, it is not well understood how astrocytes are impacted by aging, nor how they contribute to neuronal dysfunction and disease risk as organisms age. H...

    Authors: Holly K. Gildea and Shane A. Liddelow
    Citation: Molecular Neurodegeneration 2025 20:21
  33. The integrated stress response (ISR) is a conserved network in eukaryotic cells that mediates adaptive responses to diverse stressors. The ISR pathway ensures cell survival and homeostasis by regulating protei...

    Authors: Maria Astrid Bravo-Jimenez, Shivangi Sharma and Soheila Karimi-Abdolrezaee
    Citation: Molecular Neurodegeneration 2025 20:20
  34. Parkinson disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy are synucleinopathies, characterized by neuronal loss, gliosis and the abnormal deposition of α-synuclein in vulnerable areas...

    Authors: Ambra Stefani, Elena Antelmi, Dario Arnaldi, Isabelle Arnulf, Emmanuel During, Birgit Högl, Michele M. T. Hu, Alex Iranzo, Russell Luke, John Peever, Ronald B. Postuma, Aleksandar Videnovic and Ziv Gan-Or
    Citation: Molecular Neurodegeneration 2025 20:19
  35. Axon regeneration after injury to the central nervous system (CNS) is limited by an inhibitory environment but also because injured neurons fail to initiate expression of regeneration associated genes (RAGs). ...

    Authors: Callan L. Attwell, Inés Maldonado-Lasunción, Ruben Eggers, Bastiaan A. Bijleveld, Ward M. Ellenbroek, Natascha Siersema, Lotte Razenberg, Dédé Lamme, Nitish D. Fagoe, Ronald E. van Kesteren, August B. Smit, Joost Verhaagen and Matthew R. J. Mason
    Citation: Molecular Neurodegeneration 2025 20:18
  36. Cortical atrophy is a common manifestation in behavioral variant frontotemporal degeneration (bvFTD), exhibiting spatial heterogeneity across various genetic subgroups, which may be driven by distinct biologic...

    Authors: Ting Shen, Jacob W. Vogel, Vivianna M. Van Deerlin, EunRan Suh, Laynie Dratch, Jeffrey S. Phillips, Lauren Massimo, Edward B. Lee, David J. Irwin and Corey T. McMillan
    Citation: Molecular Neurodegeneration 2025 20:17
  37. Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterized by the loss of both upper and lower motor neurons, leading to progressive paralysis. Both genetic alterations and epigene...

    Authors: Ali Yousefian-Jazi, Suhyun Kim, Jiyeon Chu, Seung-Hye Choi, Phuong Thi Thanh Nguyen, Uiyeol Park, Min-gyeong Kim, Hongik Hwang, Kyungeun Lee, Yeyun Kim, Seung Jae Hyeon, Hyewhon Rhim, Hannah L. Ryu, Grewo Lim, Thor D. Stein, Kayeong Lim…
    Citation: Molecular Neurodegeneration 2025 20:16
  38. Cellular senescence, a hallmark of aging, has been implicated in Alzheimer’s disease (AD) pathogenesis. Cholesterol accumulation is known to drive cellular senescence; however, its underlying mechanisms are no...

    Authors: Shaowei Wang, Boyang Li, Jie Li, Zhiheng Cai, Cristelle Hugo, Yi Sun, Lu Qian, Julia TCW, Helena C. Chui, Dante Dikeman, Isaac Asante, Stan G. Louie, David A. Bennett, Zoe Arvanitakis, Alan T. Remaley, Bilal E. Kerman…
    Citation: Molecular Neurodegeneration 2025 20:15
  39. Gastrointestinal (GI) involvement in Lewy body diseases (LBDs) has been observed since the initial descriptions of patients by James Parkinson. Recent experimental and human observational studies raise the pos...

    Authors: Timothy R. Sampson, Malú Gámez Tansey, Andrew B. West and Rodger A. Liddle
    Citation: Molecular Neurodegeneration 2025 20:14
  40. Many diseases and disorders of the nervous system suffer from a lack of adequate therapeutics to halt or slow disease progression, and to this day, no cure exists for any of the fatal neurodegenerative disease...

    Authors: Francisco J. Garcia and Myriam Heiman
    Citation: Molecular Neurodegeneration 2025 20:13
  41. Alzheimer’s disease (AD) is a debilitating neurodegenerative disease that is marked by profound neurovascular dysfunction and significant cell-specific alterations in the brain vasculature. Recent advances in ...

    Authors: Soumilee Chaudhuri, Minyoung Cho, Julia C. Stumpff, Paula J. Bice, Özkan İş, Nilüfer Ertekin-Taner, Andrew J. Saykin and Kwangsik Nho
    Citation: Molecular Neurodegeneration 2025 20:12
  42. Alzheimer’s disease (AD) is among the most devastating neurodegenerative disorders with limited treatment options. Emerging evidence points to the involvement of lipid dysregulation in the development of AD. N...

    Authors: Sijia He, Ziying Xu and Xianlin Han
    Citation: Molecular Neurodegeneration 2025 20:11
  43. α-Synucleinopathies constitute a spectrum of neurodegenerative disorders, including Parkinson’s disease (PD), Lewy body dementia (LBD), Multiple System Atrophy (MSA), and Alzheimer’s disease concurrent with LB...

    Authors: Grace Kuo, Ramhari Kumbhar, William Blair, Valina L. Dawson, Ted M. Dawson and Xiaobo Mao
    Citation: Molecular Neurodegeneration 2025 20:10
  44. Apolipoprotein E ε4 (APOE4) is the strongest genetic risk factor for late-onset Alzheimer’s disease (LOAD). A recent case report identified a rare variant in APOE, APOE3-R136S (Christchurch), proposed to confer r...

    Authors: Kristine M. Tran, Nellie E. Kwang, Claire A. Butler, Angela Gomez-Arboledas, Shimako Kawauchi, Cassandra Mar, Donna Chao, Rocio A. Barahona, Celia Da Cunha, Kate I. Tsourmas, Zechuan Shi, Shuling Wang, Sherilyn Collins, Amber Walker, Kai-Xuan Shi, Joshua A. Alcantara…
    Citation: Molecular Neurodegeneration 2025 20:9